Return On Invested Capital
36%
Trailing 12 months · Through 31 Jul 2026
Assumes a 21% tax rate.
Cash unavailable; invested capital does not subtract cash.
YoY relative change: -105%
Vitro Biopharma, Inc. financial metrics
Period Q3 2026 · Filed 18 Sep 2026
Key metrics snapshot
Return On Equity
91%
Trailing 12 months · Through 31 Jul 2026
YoY relative change: +9.9%
Return On Assets
-216%
Trailing 12 months · Through 31 Jul 2026
YoY relative change: +53%
Operating Margin
-237%
Trailing 12 months · Through 31 Jul 2026
YoY relative change: -15%
Current Ratio
1.77x
Period-end balance · Through 31 Jul 2026
YoY relative change: +3992%
Quick Ratio
1.68x
Period-end balance · Through 31 Jul 2026
YoY relative change: +5234%
Debt-to-equity
-0.09x
Period-end balance · Through 31 Jul 2026
YoY relative change: -90%
Revenues YoY
-3.6%
Trailing 12 months · Through 31 Jul 2026
NetIncomeLoss YoY
-99%
Trailing 12 months · Through 31 Jul 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Invested Capital |
36%
Trailing 12 months · 31 Jul 2026
Assumes a 21% tax rate. Cash unavailable; invested capital does not subtract cash.
|
-105% |
| Return On Equity |
91%
Trailing 12 months · 31 Jul 2026
|
+9.9% |
| Return On Assets |
-216%
Trailing 12 months · 31 Jul 2026
|
+53% |
| Operating Margin |
-237%
Trailing 12 months · 31 Jul 2026
|
-15% |
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
1.77x
Period-end balance · 31 Jul 2026
|
+3992% |
| Quick Ratio |
1.68x
Period-end balance · 31 Jul 2026
|
+5234% |
| Debt-to-equity |
-0.09x
Period-end balance · 31 Jul 2026
|
-90% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
-3.6%
Trailing 12 months · 31 Jul 2026
|
|
| NetIncomeLoss YoY |
-99%
Trailing 12 months · 31 Jul 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
4,517,651
Period-end balance · 18 Sep 2026
|
+1.3% |
| Common Stock, Shares, Outstanding |
4,517,651
Period-end balance · 31 Jul 2026
|
+1.3% |
| Common Stock, Value, Issued |
$4,517
Period-end balance · 31 Jul 2026
|
+1.3% |
| Weighted Average Number of Shares Outstanding, Basic |
5,901,151
Reported period · 31 Jul 2026
|
+0.98% |
| Weighted Average Number of Shares Outstanding, Diluted |
5,901,151
Reported period · 31 Jul 2026
|
+0.98% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Additional Paid in Capital |
$37,411,997
Period-end balance · 31 Jul 2026
|
+17% |
| Amortization of Intangible Assets |
$22,857
Trailing 12 months · 31 Jul 2026
|
-47% |
| Assets |
$10,250,062
Period-end balance · 31 Jul 2026
|
+121% |
| Assets, Current |
$6,165,869
Period-end balance · 31 Jul 2026
|
+855% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$5,737,675
Period-end balance · 31 Jul 2026
|
+3177% |
| Common Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 31 Jul 2026
|
0% |
| Common Stock, Shares Authorized |
19,230,770
Period-end balance · 31 Jul 2026
|
0% |
| Common Stock, Shares, Issued |
4,517,651
Period-end balance · 31 Jul 2026
|
+1.3% |
| Depreciation |
$53,865
Trailing 12 months · 31 Jul 2026
|
-57% |
| Earnings Per Share, Basic |
-3.3
Trailing 12 months · 31 Jul 2026
|
-93% |
| Earnings Per Share, Diluted |
-3.3
Trailing 12 months · 31 Jul 2026
|
-93% |
| Goodwill |
$3,171,581
Period-end balance · 31 Jul 2026
|
0% |
| Intangible Assets, Net (Excluding Goodwill) |
$304,751
Period-end balance · 31 Jul 2026
|
-9.1% |
| Inventory, Net |
$296,211
Period-end balance · 31 Jul 2026
|
+70% |
| Lessee, Operating Lease, Liability, to be Paid |
$307,477
Period-end balance · 31 Jul 2026
|
-35% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$84,609
Period-end balance · 31 Jul 2026
|
-49% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$67,734
Period-end balance · 31 Jul 2026
|
0% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$67,734
Period-end balance · 31 Jul 2026
|
-20% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$47,563
Period-end balance · 31 Jul 2026
|
-78% |
| Liabilities |
$5,946,173
Period-end balance · 31 Jul 2026
|
-64% |
| Liabilities and Equity |
$10,250,062
Period-end balance · 31 Jul 2026
|
+121% |
| Liabilities, Current |
$3,484,956
Period-end balance · 31 Jul 2026
|
-77% |
| Operating Income (Loss) |
$4,827,253
Trailing 12 months · 31 Jul 2026
|
+18% |
| Operating Lease, Liability |
$259,914
Period-end balance · 31 Jul 2026
|
+1.7% |
| Operating Lease, Liability, Current |
$89,173
Period-end balance · 31 Jul 2026
|
-20% |
| Operating Lease, Liability, Noncurrent |
$170,741
Period-end balance · 31 Jul 2026
|
+19% |
| Operating Lease, Right-of-Use Asset |
$259,914
Period-end balance · 31 Jul 2026
|
+1.7% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.1
Period-end balance · 31 Jul 2026
|
0% |
| Other Assets, Noncurrent |
$8,438
Period-end balance · 31 Jul 2026
|
0% |
| Preferred Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 31 Jul 2026
|
0% |
| Preferred Stock, Shares Authorized |
5,000,000
Period-end balance · 31 Jul 2026
|
0% |
| Property, Plant and Equipment, Gross |
$1,228,186
Period-end balance · 31 Jul 2026
|
+16% |
| Property, Plant and Equipment, Net |
$170,576
Period-end balance · 31 Jul 2026
|
+198% |
| Research and Development Expense |
$673,659
Trailing 12 months · 31 Jul 2026
|
+10% |
| Retained Earnings (Accumulated Deficit) |
$60,436,748
Period-end balance · 31 Jul 2026
|
-37% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$2,032,893
Trailing 12 months · 31 Jul 2026
|
-3.6% |
| Share-based Payment Arrangement, Noncash Expense |
$1,073,741
Trailing 12 months · 31 Jul 2026
|
-22% |
| Stockholders' Equity Attributable to Parent |
$23,104,234
Period-end balance · 31 Jul 2026
|
-91% |
Comparisons, sources and research notes
Sources and sharing
Vitro Biopharma, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2026
- Latest reported value
- Return On Invested Capital 36%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2026.
- Most recent SEC facts end date on this page: 18 Sep 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Vitro Biopharma, Inc.
Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
18 Sep 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 18 Sep 2026.
Benchmark Context
How Return On Invested Capital compares
Return On Invested Capital is down about 105% versus the comparable prior period.
Compared with
Compared with Vitro Biopharma, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Invested Capital already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- Vitro Biopharma, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2026.
- Headline metric: Return On Invested Capital 36%.
Change
- Return On Invested Capital YoY relative change: -105%.
- Most recent SEC facts end date: 18 Sep 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-09-18) highlights Return On Invested Capital 35.5%, Return On Equity 91.2%, and Return On Assets -215.7%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
Fair value per share
$9.09
Market price
n/a
PEG ratio
n/a
Enterprise value
$57.11M
Equity value
$53.61M
DCF fair value scenarios
Bear
$6.63
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
$9.09
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
$12.95
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $3.92M
- Trailing SEC FCF
- Reported FCF
- $3.92M
- Net income
- $16.04M
- EBITDA
- $3.21M
- Cash
- $5.74M
- Debt
- $2.24M
- Equity
- $23.1M
- Shares
- 5,901,151
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Vitro Biopharma, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: -3.6%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
56.3/100
Caution Confidence high
Return On Invested Capital
36%
Metric score 100.0/100
Return On Equity
91%
Metric score 100.0/100
Return On Assets
-216%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.77x
- Quick Ratio
- 1.68x
- Debt to Equity
- -0.09x
Strengths
Return On Invested Capital, Return On Equity, and Current Ratio
Watchpoints
Return On Assets, Operating Margin, and Debt-to-equity
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first